Nintedanib, functioning as a tyrosine kinase inhibitor (TKI), simultaneously targets and inhibits receptors for several key growth factors involved in pulmonary fibrosis, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) [23]. The gene discussed is VEGFA; the disease is pulmonary fibrosis.